U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

Substance Class Protein
Created
by admin
on Wed Apr 02 05:36:18 GMT 2025
Edited
by admin
on Wed Apr 02 05:36:18 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1|TOXIN CONJUGATE
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
W95G28K44S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Trastuzumab Vedotin
INN  
Official Name English
MRG-002
Preferred Name English
Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody; conjugated to auristatin E
Common Name English
MRG 002 [WHO-DD]
Common Name English
TRASTUZUMAB--VCMMAE CONJUGATE
Common Name English
MRG002
Code English
trastuzumab vedotin [INN]
Common Name English
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 898822
Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025
Code System Code Type Description
SMS_ID
300000050047
Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025
PRIMARY
INN
12531
Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025
PRIMARY
NCI_THESAURUS
C174205
Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025
PRIMARY
CAS
2740607-04-7
Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025
PRIMARY
FDA UNII
W95G28K44S
Created by admin on Wed Apr 02 05:36:18 GMT 2025 , Edited by admin on Wed Apr 02 05:36:18 GMT 2025
PRIMARY
From To
4_134 4_194
4_23 4_88
3_134 3_194
3_23 3_88
2_370 2_428
2_264 2_324
2_223 4_214
2_147 2_203
2_22 2_96
1_370 1_428
1_264 1_324
1_232 2_232
1_229 2_229
1_223 3_214
1_147 1_203
1_22 1_96
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_300
N 2_300
Related Record Type Details
CONJUGATE COMPONENT->CONJUGATE
CONJUGATE COMPONENT->CONJUGATE
CONJUGATE COMPONENT->CONJUGATE
TARGET->CONJUGATED TOXIN
MRG002 potently inhibited proliferation of HER2 expressing cancer cells in vitro with IC50 ranged from 1.8±0.8 to 59.9±8.9 ng/mL,
Related Record Type Details
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION RESIDUE_SPECIFIC Cysteine Cysteinyl vedotin 6603L01WUR
AMINO ACID REMOVAL [1_450] [2_450] C-TERMINUS Amount: LYSINE K3Z4F929H6
AMINO_ACID_SUBSTITUTION Amount: PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL